Results 41 to 50 of about 492 (136)

Real-world safety of aliskiren in primary hypertension: A cross-database study. [PDF]

PLoS ONE
Hypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains ...
Meirong Shan, Qian Guo, Ruofei Li, Ni Li, Yanhua Fu, Huanyu Qi, Ge Zhang, Qian Wang, Xingli Xu, Jinchuan Lai   +9 more
doaj   +2 more sources

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +2 more sources

Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles [PDF]

Scientific Reports
Viloxazine and dextroamphetamine as newly approved drugs for the medical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in recent years give new options for the treating of related disorders, including anxiety, and depression.
Lijun Wang, Qingyang Kong, Yixuan Li
doaj   +2 more sources

Original research a real-world study of adverse events of nafamostat mesylate and sodium citrate based on the world health organization-VigiAccess database [PDF]

Frontiers in Pharmacology
AimsWhile nafamostat mesylate (NM) and sodium citrate serve as commonly used extracorporeal anticoagulants in clinical practice, the characteristics and potential risks of their adverse events (AEs) need to be systematically evaluated.
Mengting Xu, Ziyi Wang, Binbin Yu
doaj   +2 more sources

Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events [PDF]

Frontiers in Pharmacology
BackgroundTarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC).
Yingyong Ou, Xianxian Zhong, Mei Mei, Xiao Gu, Shanshan Luo, Gaoyu Chen, Xuqin Xie, Desheng Sun   +7 more
doaj   +2 more sources

Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis [PDF]

Frontiers in Pharmacology
BackgroundTumor necrosis factor-α (TNF-α) inhibitors are widely used for chronic inflammatory diseases, but their effects on male sexual health remain uncertain.
Yi Chu, Min Luo, Wenyu Li, Xuehong Wang, Yuqian Zhou   +4 more
doaj   +2 more sources

Common osteoporosis drug associated with increased rates of depression and anxiety [PDF]

Scientific Reports, 2021
Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease.
Dro Keshishi, Tigran Makunts, Ruben Abagyan   +2 more
doaj   +2 more sources

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases [PDF]

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +2 more sources

Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess. [PDF]

PLoS One
Introduction Antihistamines like azelastine and levocabastine are key in treating allergies, including allergic rhinitis, conjunctivitis, and urticaria.
Li Y, Zhu J, Guo Q, Liao J, Li L, Hu J, Zhang X.   +6 more
europepmc   +2 more sources

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases [PDF]

Frontiers in Pharmacology
Objectives: This study aims to investigate adverse events (AEs) and adverse drug reactions (ADRs) associated with pirfenidone and nintedanib, two antifibrotic drugs used to treat idiopathic pulmonary fibrosis (IPF).Methods: Reporting odds ratio (ROR) and
Menglin He, Taoran Yang, Jian Zhou, Rurong Wang, Xuehan Li   +4 more
doaj   +2 more sources